Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.65 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.65 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.65 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.65 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20699834 | 0.88 | PI4KA (0.62) | PI4KAPI4K2BPI4K2API4KBP2RY12 | |
| SCHEMBL12379237 | 0.88 | PI4KA (0.62) | PI4KAPI4K2BPI4K2API4KBP2RY12 | |
| SCHEMBL18571809 | 0.88 | PI4KA (0.62) | PI4KAPI4K2BPI4K2API4KBP2RY12 | |
| SCHEMBL30827092 | 0.85 | PI4KA (0.62) | PI4KAPI4K2BPI4K2API4KBP2RY12 | |
| SCHEMBL22402681 | 0.85 | PI4KA (0.62) | PI4KAPI4K2BPI4K2API4KBP2RY12 | |
| SCHEMBL26361736 | 0.85 | PI4KA (0.62) | PI4KAPI4K2BPI4K2API4KBP2RY12 | |
| SCHEMBL22601403 | 0.85 | PI4KA (0.62) | PI4KAPI4K2BPI4K2API4KBP2RY12 | |
| SCHEMBL16378775 | 0.85 | PI4KA (0.62) | PI4KAPI4K2BPI4K2API4KBP2RY12 | |
| SCHEMBL29444514 | 0.85 | PI4KA (0.62) | PI4KAPI4K2BPI4K2API4KBP2RY12 | |
| SCHEMBL1097616 | 0.85 | PI4KA (0.62) | PI4KAPI4K2BPI4K2API4KBP2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318798-B2 | Therapeutic agent for neurodegenerative disease | NATIONAL UNIVERSITY CORPORATION HOKKALDO UNIVERSITY (JP) | 2012-11-27 | — | — | US | disclosed |
| US-20090233872-A1 | Therapeutic Agent for Neurodegenerative Disease | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233872-A1 | Therapeutic Agent for Neurodegenerative Disease | PARK7, HSPD1, FASTKD1 | PI4KA 1685/4885PI4K2B 2158/4885PI4K2A 1461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.